| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $5.4M | — | +496.8% |
| SG&A Expense | $6.9M | — | +176.1% |
| Net Income | -$6.5M | — | -109.3% |
| EPS (Basic) | -$0.13 | — | -44.4% |
| EPS (Diluted) | -$0.13 | — | -44.4% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $577.5M | +184.1% | +368.5% |
| Short-term Investments | $280K | — | — |
| Accounts Receivable | $86K | -65.4% | — |
| Current Assets | $580.8M | +183.8% | +352.1% |
| Total Assets | $606.1M | +165.1% | +351.8% |
| Current Liabilities | $4.3M | +13.2% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.0M | — | -23.0% |
| Investing Cash Flow | -$3.1M | — | +14.1% |
| Financing Cash Flow | $381.3M | — | +275.5% |
| +72.1% |
| Total Liabilities | $6.5M | +6.4% | +58.5% |
| Stockholders' Equity | $599.6M | +169.4% | +361.0% |